Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessia Ligresti

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
The Journal of Cell Biology|November 12, 2003
Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brainTiziana Bisogno, Fiona Howell, Gareth Williams, et al.
Journal of Medicinal Chemistry|May 3, 2012
Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonistsSerena Pasquini, Claudia Mugnaini, Alessia Ligresti, et al.
Endocrinology|February 6, 2010
The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinomaMaurizio Guida, Alessia Ligresti, Daniele De Filippis, et al.
European Journal of Medicinal Chemistry|April 10, 2012
Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffoldClementina Manera, Giuseppe Saccomanni, Anna Maria Malfitano, et al.
Molecules (Basel, Switzerland)|July 14, 2023
Systematic Modification of the Substitution Pattern of the 7-Hydroxy-5-oxopyrazolo[4,3-<i>b</i>]pyridine-6-carboxamide Scaffold Enabled the Discovery of New Ligands with High Affinity and Selectivity for the Cannabinoid Type 2 ReceptorClaudia Mugnaini, Magdalena Kostrzewa, Marta Casini, et al.
Pharmacological Research|February 3, 2023
Cannabidiol alters mitochondrial bioenergetics via VDAC1 and triggers cell death in hormone-refractory prostate cancerAli Mokhtar Mahmoud, Magdalena Kostrzewa, Viviana Marolda, et al.
Cell Death Discovery|March 5, 2023
Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancerFederica Maccarinelli, Daniela Coltrini, Silvia Mussi, et al.
Journal of Medicinal Chemistry|June 10, 2020
Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3-<i>b</i>]pyridine-6-carboxamide Derivatives with Antiosteoarthritic Activity In VivoClaudia Mugnaini, Magdalena Kostrzewa, Marta Bryk, et al.
International Journal of Molecular Sciences|February 27, 2026
Targeting TRPA1 with Novel Synthetic Compounds Based on Different Scaffolds to Reduce Acute and Chronic PainAlessia Agata Corallo, Samuele Maramai, Carlotta Noli, et al.
Cancer Research|February 8, 2020
Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate CancerMarianna Cerasuolo, Federica Maccarinelli, Daniela Coltrini, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
The Journal of Cell Biology|November 12, 2003
Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brainTiziana Bisogno, Fiona Howell, Gareth Williams, et al.
Journal of Medicinal Chemistry|May 3, 2012
Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonistsSerena Pasquini, Claudia Mugnaini, Alessia Ligresti, et al.
Endocrinology|February 6, 2010
The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinomaMaurizio Guida, Alessia Ligresti, Daniele De Filippis, et al.
European Journal of Medicinal Chemistry|April 10, 2012
Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffoldClementina Manera, Giuseppe Saccomanni, Anna Maria Malfitano, et al.
Molecules (Basel, Switzerland)|July 14, 2023
Systematic Modification of the Substitution Pattern of the 7-Hydroxy-5-oxopyrazolo[4,3-<i>b</i>]pyridine-6-carboxamide Scaffold Enabled the Discovery of New Ligands with High Affinity and Selectivity for the Cannabinoid Type 2 ReceptorClaudia Mugnaini, Magdalena Kostrzewa, Marta Casini, et al.
Pharmacological Research|February 3, 2023
Cannabidiol alters mitochondrial bioenergetics via VDAC1 and triggers cell death in hormone-refractory prostate cancerAli Mokhtar Mahmoud, Magdalena Kostrzewa, Viviana Marolda, et al.
Cell Death Discovery|March 5, 2023
Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancerFederica Maccarinelli, Daniela Coltrini, Silvia Mussi, et al.
Journal of Medicinal Chemistry|June 10, 2020
Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3-<i>b</i>]pyridine-6-carboxamide Derivatives with Antiosteoarthritic Activity In VivoClaudia Mugnaini, Magdalena Kostrzewa, Marta Bryk, et al.
International Journal of Molecular Sciences|February 27, 2026
Targeting TRPA1 with Novel Synthetic Compounds Based on Different Scaffolds to Reduce Acute and Chronic PainAlessia Agata Corallo, Samuele Maramai, Carlotta Noli, et al.
Cancer Research|February 8, 2020
Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate CancerMarianna Cerasuolo, Federica Maccarinelli, Daniela Coltrini, et al.
Pageof 12